Literature DB >> 16402362

Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations.

Hyun Ju Kang1, Kwi Hye Koh, Eungi Yang, Kwon Tae You, Hee Jin Kim, Young-Ki Paik, Hoguen Kim.   

Abstract

Most gastrointestinal stromal tumors (GIST) have activating mutations in either KIT or PDGFRA. However, a small subset of GIST lacks either mutation. To investigate the molecular characteristics of GIST according to mutation type, protein expression profiles in 12 GIST (2 cases with PDGFRA mutations, 8 cases with KIT mutations and 2 cases lacking either mutation) were analyzed using 2-DE and MALDI-TOF-MS. Comparative analysis of the respective spot patterns using 2-DE showed that 15 proteins were differently expressed according to the mutation status. Expression levels of septin and heat shock protein (HSP) 27 were increased in GIST with KIT mutations and annexin V was overexpressed in GIST lacking either mutation. Among the 15 proteins, overexpression of 5 proteins [annexin V, high mobility group protein 1 (HMGB1), C13orf2, glutamate dehydrogenase 1 and fibrinogen beta chain] and decreased expression of RoXaN correlated with a higher tumor grade. These findings suggest that differential protein expression can be used as a diagnostic biomarker. Moreover, it may play a role in the development and progression of GIST according to activating mutation type, as these proteins have been shown to be involved in tumor metastasis, apoptosis and immune response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402362     DOI: 10.1002/pmic.200500372

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  14 in total

1.  Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma.

Authors:  Michael A Kuzyk; Derek Smith; Juncong Yang; Tyra J Cross; Angela M Jackson; Darryl B Hardie; N Leigh Anderson; Christoph H Borchers
Journal:  Mol Cell Proteomics       Date:  2009-05-01       Impact factor: 5.911

2.  Laparoscopic Transgastric Resection of a Gastric Submucosal Tumor near Esophagogastric Junction with Concomitant Sleeve Gastrectomy: a Video Case Report.

Authors:  Saeed Alshlwi; Aly Elbahrawy; Hussam Alamri; Sara Najmeh; Rajesh Aggarwal; Sebastian Demyttenaere; Olivier Court; Amin Andalib
Journal:  Obes Surg       Date:  2017-02       Impact factor: 4.129

3.  Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers.

Authors:  Nina Kočevar; Federico Odreman; Alessandro Vindigni; Snježana Frković Grazio; Radovan Komel
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 4.  Proteomic analysis of soft tissue sarcoma.

Authors:  Yoshiyuki Suehara
Journal:  Int J Clin Oncol       Date:  2011-03-09       Impact factor: 3.402

Review 5.  Contribution of oncoproteomics to cancer biomarker discovery.

Authors:  William C S Cho
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

Review 6.  A Review: Proteomics in Nasopharyngeal Carcinoma.

Authors:  Ze-Tan Chen; Zhong-Guo Liang; Xiao-Dong Zhu
Journal:  Int J Mol Sci       Date:  2015-07-08       Impact factor: 5.923

7.  GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.

Authors:  Eui Jin Lee; Guhyun Kang; Shin Woo Kang; Kee-Taek Jang; Jeeyun Lee; Joon Oh Park; Cheol Keun Park; Tae Sung Sohn; Sung Kim; Kyoung-Mee Kim
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

8.  Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.

Authors:  Jerzy Ostrowski; Marcin Polkowski; Agnieszka Paziewska; Magdalena Skrzypczak; Krzysztof Goryca; Tymon Rubel; Katarzyna Kokoszyñska; Piotr Rutkowski; Zbigniew I Nowecki; Anna Jerzak Vel Dobosz; Dorota Jarosz; Wlodzimierz Ruka; Lucjan S Wyrwicz
Journal:  BMC Cancer       Date:  2009-11-27       Impact factor: 4.430

9.  Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.

Authors:  Michael Karanikas; Nikolaos Machairiotis; Paul Zarogoulidis; Aikaterini Stylianaki; Nikolaos Corcoutsakis; Alexandros Mitrakas; Panagiotis Touzopoulos; Nikolaos Lyratzopoulos; George Kouklakis; Manolis Spanoudakis; Alexandros Polychronidis
Journal:  Onco Targets Ther       Date:  2012-12-12       Impact factor: 4.147

Review 10.  The current state of proteomics in GI oncology.

Authors:  Ying Lin; William S Dynan; Jeffrey R Lee; Zhao-Hua Zhu; Robert R Schade
Journal:  Dig Dis Sci       Date:  2008-12-23       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.